At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 90 enrolled
Drug / intervention
Zalutumumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Single Arm Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF Receptor Antibody, in Combination With Best Supportive Care, in Patients With Non-Curable Squamous Cell Carcinoma of the Head and Neck Who Have Failed Standard Platinum-based Chemotherapy.
In Brief
A Phase 2 clinical trial evaluating Zalutumumab for Head and Neck Cancer and Squamous Cell Cancer. Completed, enrolled 90 participants across 48 sites in 11 countries.
Detailed Summary
Treatment, In combination with BSC, Open-label, Single arm, Efficacy Study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Cancer, Squamous Cell Cancer
CountriesAustria, Chile, Colombia, Czechia, Germany, Israel, Italy, Peru, Portugal, Slovakia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2007
Enrollment StartJan 2008
Primary CompletionAug 2011
TodayJul 2026
First PostedOct 11, 2007
Enrollment StartJan 1, 2008
Primary CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 18.7 years ago
Interventions
Zalutumumabdrug
Individual dose titration weekly i.v. doses